Page 100 - Drug Class Review
P. 100
Page 80 of 205
Drug Effectiveness Review Project
rivastigmine 6-12 mg/d 26 weeks 231
To evaluate the efficacy and safety of RIV tartrate for patients with AD
rivastigmine 1-4 mg/d 26 weeks 233 Age between 45 and 89 years; non-childbearing potential for females; criteria for AD according to DSM- IV; probable AD according to NINCDS/ADRDA criteria; mild-to-moderate impairment based on MMSE score between 10 and 26; head CT or MRI consistent with AD within 12 months of inclusion; responsible Severe and unstable medical illnesses; use of anticholinergics ACh precursor health food supplements, memory enhancers, insulin, and psychotic drugs must be discontinued
Drugs Authors: Corey-Bloom et al. 55 Setting: Multi-center (22) placebo N/A 26 weeks 235 caregiver who provided written consent Occasional use of chloral hydrate for agitation or insomnia
Alzheimer Year: 1998 Country: US Novartis Study design: RCT Sample size: 699
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
